Special Issue

Breast Cancer Brain Metastasis and Leptomeningeal Disease

Message from the Guest Editors

Brain metastases are the most common intracranial malignancy. About one in five patients with metastatic breast cancer will develop brain metastases (BMs) during their disease course. Specifically, HER2-positive and triple-negative breast cancer subtypes have higher incidences of BMs, with recent data suggesting an increase in the overall incidence of MBC-related BMs in Western countries. Historically, BMs were associated with poor prognoses; however, novel approaches and therapies are starting to change the paradigm in patients with MBC-related BMs. Furthermore, BMs from metastatic breast cancer were found to have unique clinical and molecular features when compared to other tumor types, highlighting the need for further specific investment and research in this field. Our goal in the current Special Issue of Cancers is to shed light on the latest advancements in this perplexing field and raise awareness of the most significant contemporary challenges in the diagnosis, monitoring, treatment, and prognostication of patients with metastatic breast cancer and BMs.

Guest Editors

Dr. Albert Grinshpun
Dana-Farber Cancer Institute, Boston, MA, USA

Dr. Sarah Sammons
Dana-Farber Cancer Institute, Boston, MA, USA

Dr. Nancy U. Lin
1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
2. Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
3. Harvard Medical School, Boston, MA, USA

Deadline for manuscript submissions

closed (15 March 2025)

Cancers

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:
free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)